Content of matrix metalloproteinases in the intraocular fluid of patients with primary open-angle glaucoma

Author: Chernykh V.V.¹, Konenkov V.I.², Ermakova O.V.³, Orlov N.B.⁴, Trunov А.N.⁵

Abstract

Aim of the study was to investigate the content of matrix metalloproteinases 2, 3, 9, in the intraocular fluid of patients with a developed stage of primary open-angle glaucoma. Material and methods. The study included 47 patients with advanced stage of primary open-angle glaucoma. The diagnosis is based on ophthalmological examination, including visual acuity, binocular ophthalmoscopy, spheroperimetry, echoophthalmography, optical coherence tomography, intraocular pressure measurement. Exclusion criteria were acute and exacerbation of chronic inflammatory diseases of the organ of vision, diabetic retinopathy, neovascular glaucoma, uveitis, hemophthalmia, autoimmune and tumor processes of any localization, as well as acute and exacerbations of chronic inflammatory diseases of any organs and systems. Patients who took for normalization of intraocular pressure drugs containing analogues of prostaglandins, that could activate the inflammatory process, were excluded from the study. 26 patients with a diagnosis of uncomplicated cataract made up a comparison group. All patients underwent determination of matrix metalloproteinases (MMP) 2, 3, 9 in the intraocular fluid. Results. Concentration of MMP-2 but not MMP-3 or MMP-9 is statistically significantly higher in the intraocular fluid of patients with a developed stage of primary open-angle glaucoma compared to individuals with uncomplicated cataracts. This may indicate importance of MMP-2 in the development of a local aseptic inflammatory process, impaired extracellular matrix and «remodeling» of the tissue structures of the organ of vision, leading to disruption of the outflow of intraocular fluid, which is an important factor in the pathogenesis of primary open-angle glaucoma.

Key words

primary open-angle glaucoma, matrix metalloproteinases, intraocular fluid

References

1. Chua J., Vania M., Cheung C.M., Ang M., Chee S.P., Yang H., Li.J, Wong T.T. Expression profile of inflammatory cytokines in aqueous from glaucomatous eyes. Mol. Vis. 2012; 18: 431–438.

2. Khalef N., Labib H., Helmy H., El Hamid M.A., Moemen L, Fahmy I. Levels of cytokines in the aqueous humor of eyes with primary open angle glaucoma, pseudoexfoliation glaucoma and cataract. Electron Physician. 2017; 9 (2): 3833-3837. doi:10.19082/3833

3. Kokubun T., Tsuda S., Kunikata H., Yasuda M., Himori N., Kunimatsu-Sanuki S., Maruyama K., Nakazawa T. Characteristic profiles of inflammatory cytokines in the aqueous humor of glaucomatous eyes. Ocul. Immunol. Inflamm. 2018; 26 (8): 1177-1188. doi: 10.1080/09273948.2017.1327605

4. Chernykh V.V., Ermakova O.V., Orlov N.B., Obukhova O.O., Gorbenko O.M., Shvayuk A.P., Eremina A.V., Trunov A.N. Features of the content of proinflammatory cytokines in lacrimal and intraocular fluid in patients with primary open-angle glaucoma. Sibirskiy nauchnyy medtsinskiy zhurnal = Siberian Scientific Medical Journal. 2018; 38 (5): 5-10. [In Russian]. doi: 10.15372/SSMJ20180501

5. Pantalon A., Obadă O., Constantinescu D., Feraru C., Chiseliţă D. Inflammatory model in patients with primary open angle glaucoma and diabetes. Int. J. Ophthalmol. 2019; 12 (5): 795–801. doi: 10.18240/ijo.2019.05.15

6. Chernykh V.V., Konenkov V.I., Ermakova O.V., Orlov N.B., Obukhova O.O., Eremina A.V., Trunov A.N. Сontent of cytokines and growth factors in the intraocular fluid of patients with primary open-angle glaucoma. Byulleten' sibirskoy meditsiny = Bulletin of Siberian Medicine. 2019; 18 (1): 257-265. [In Russian]. doi: 10.20538/1682-0363-2019-1-257-265

7. Berge T.J.C., Fazil Z., Van den Born I., Wolfs R.C.W., Schreurs M.W.J., Dik W.A., Rothova A. Intraocular cytokine profile and autoimmune reactions in retinitis pigmentosa, age-related macular degeneration, glaucoma and cataract. Acta Ophthalmol. 2019; 97 (2): 185–192. doi: 10.1111/aos.13899

8. Cui N., Hu M., Khalil R.A. Biochemical and biological attributes of matrix metalloproteinases. Prog. Mol. Biol. Transl Sci. 2017; 147: 1-73. doi: 10.1016/bs.pmbts.2017.02.005

9. Chen Q., Jin M., Yang F., Zhu J., Xiao Q., Zhang L. Matrix metalloproteinases: inflammatory regulators of cell behaviors in vascular formation and remodeling. Mediators Inflamm. 2013; 2013: 928315. doi: 10.1155/2013/928315

10. Nissinen L., Kähäri V.M. Matrix metalloproteinases in inflammation. Biochim. Biophys. Acta. 2014; 1840 (8): 2571-2580. doi: 10.1016/j.bbagen.2014.03.007

11. Roupakia E., Markopoulos G.S., Kolettas E. IL-12-mediated transcriptional regulation of matrix metalloproteinases. Biosci. Rep. 2018; 38 (3): BSR20171420. doi: 10.1042/BSR20171420

12. Singh S., Maniakis-Grivas G., Singh U.K., Asher R.M., Mauri F., Elkington P.T., Friedland J.S. Interleukin-17 regulates matrix metalloproteinase activity in human pulmonary tuberculosis. J. Pathol. 2018; 244 (3): 311-322. doi:10.1002/path.5013

13. Zhang J.F., Wang G.L., Zhou Z.J., Fang X.Q., Chen S., Fan S.W. Expression of matrix metalloproteinases, tissue inhibitors of metalloproteinases, and interleukins in vertebral cartilage endplate. Orthop. Surg. 2018; 10 (4): 306-311. doi: 10.1111/os.12409

14. Wang T., He C. Pro-inflammatory cytokines: The link between obesity and osteoarthritis. Cytokine Growth Factor Rev. 2018; 44: 38-50. doi: 10.1016/j.cytogfr.2018.10.002

15. De Groef L., Van Hove I., Dekeyster E., Stalmans I., Moons L. MMPs in the trabecular meshwork: promising targets for future glaucoma therapies? Invest. Ophthalmol. Vis. Sci. 2013; 54 (12): 7756-7763. doi: 10.1167/iovs.13-13088

16. Sokolov V.A., Likhvantseva V.G., Levanova O.N., Nikiforov A.A., Vygodin V.A. Expression of matrix metalloproteinases in lacrimal fluid and gene polymorphism of complement factor h (CFH) in patients with primary open-angle glaucoma. Meditsinskaya immunologiya = Medical Immunology. 2017; 19 (5): 547-556. [In Russian]. doi: 10.15789/1563-0625-2017-5-547-556

17. Nga A.D., Yap S.L., Samsudin A., Abdul-Rahman P.S., Hashim O.H., Mimiwati Z. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in the aqueous humour of patients with primary angle closure glaucoma – a quantitative study. BMC Ophthalmol. 2014; 14: 33. doi: 10.1186/1471-2415-14-33

18. Trunov A.N., Bgatova N.P., Eremina A.V., Druzhinin I.B., Pozhidaeva A.A., Trunova L.A., Chernykh V.V. New approaches to assessing the severity of inflammatory disorders in the pathogenesis of primary open-angle glaucoma. Allergologiya i immunologiya = Allergology and immunology. 2016; 17 (2): 107–111. [In Russian].

19. Sahay P., Rao A., Padhy D., Sarangi S., Das G., Reddy M.M., Modak R. Functional activity of matrix metalloproteinases 2 and 9 in tears of patients with glaucoma. Invest. Ophthalmol. Vis. Sci. 2017; 58 (6): 106-113. doi: 10.1167/iovs.17-21723

20. De Groef L., van Hove I., Dekeyster E., Stalmans I., Moons L. MMPs in the neuroretina and optic nerve: modulators of glaucoma pathogenesis and repair? Invest. Ophthalmol. Vis. Sci. 2014; 55 (3): 1953-1964. doi: 10.1167/iovs.13-13630

21. Markiewicz L., Pytel D., Mucha B., Szymanek K., Szaflik J., Szaflik J.P., Majsterek I. Altered expression levels of MMP1, MMP9, MMP12, TIMP1, and IL-1β as a risk factor for the elevated IOP and optic nerve head damage in the primary open-angle glaucoma patients. Biomed. Res. Int. 2015; 2015: 812503. doi: 10.1155/2015/812503

22. Zaleska-Żmijewska A., Strzemecka E., Wawrzyniak Z.M., Szaflik J.P. Extracellular MMP-9-based assessment of ocular surface inflammation in patients with primary open-angle glaucoma. J. Ophthalmol. 2019; 2019: 1240537. doi:10.1155/2019/1240537

23. Da Costa A.W.F., do Carmo Neto J.R., Braga Y.L.L., Silva B.A., Lamounier A.B., Silva B.O., Dos Reis M.A., de Oliveira F.A., Celes M.R.N., Machado J.R. Cardiac chagas disease: MMPs, TIMPs, galectins, and TGF-β as tissue remodelling players. Dis. Markers. 2019; 2019: 3632906. doi: 10.1155/2019/3632906

About Authors (Correspondence):

Trunov А.N., e-mail: trunov1963@yandex.ru

Full Text

snmzh_5-2020_chernyh_i_dr.pdf

Received: 28/10/2020

Accepted: 28/10/2020